Tradestie Institutional Equity Comparison Engine

CBIO vs OTLK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OTLK Overall Edge

OTLK Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Outlook Therapeutics, Inc. Common Stock (OTLK) driven by superior Valuation, Growth & Margin while CBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CBIO trades at N/M Forward P/E with -1432.6% operating margin (+0.0% YoY revenue) versus OTLK at 2.9x Forward P/E and 4781.8% operating margin (-99.4% YoY). In options structure, CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against OTLK sits in BREAKDOWN (55th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner OTLK
CBIO N/M vs OTLK 2.9x Fwd P/E
Growth & Margin Winner OTLK
Op Margin -1432.6% vs 4781.8% ยท YoY +0.0% vs -99.4%
Momentum & Technical Winner CBIO
1Y +0.5% vs -73.0% ยท 52W Pos 23% vs 10%
Options & Structure Winner CBIO
BREAKDOWN (10th %ile IV) vs BREAKDOWN (55th %ile IV)
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.05
-7.77% 1D
Market Cap $533.8M
1M Return +10.22%
1Y Return +0.54%
Forward P/E N/M
Unified AI Score
37.4 / 100 SELL
Tech 35.0 Fund 46.0 Flow 63.0 Mom 50.0
OTLK NASDAQ
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
1M Return -18.82%
1Y Return -73.04%
Forward P/E 2.9x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CBIO +0.54% OTLK -73.04% Spread: +73.58 pp (CBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CBIO Revenue OTLK Revenue CBIO Op. Margin OTLK Op. Margin Margin Edge
FY2017 N/A $0M N/A -941.4% OTLK
FY2018 N/A $0M N/A -960.1% OTLK
FY2019 N/A $10M N/A -445.6% OTLK
FY2020 $10M N/A -506.8% N/A CBIO
FY2021 $0M N/A -5470.7% N/A CBIO
FY2022 $0M N/A -63204.4% N/A CBIO
FY2023 $0M N/A -392752.9% N/A CBIO
FY2025 $10M $0M -1407.5% -4744.3% CBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CBIO (4) vs OTLK (5)
Institutional Metric CBIO OTLK Criterion Row Winner
Market Capitalization Scale $533.8M $107.1M Larger Scale CBIO
Trailing P/E Ratio Valuation N/M 2.9x Lower Multiple OTLK
Forward P/E Ratio Valuation N/M 2.9x Lower Multiple OTLK
Revenue Growth (YoY) Growth +0.0% -99.4% Higher Growth CBIO
Operating Margin (TTM) Profitability -1432.6% 4781.8% Higher Margin OTLK
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -160.8% -3.6% Higher ROE OTLK
52-Week Range Position Momentum 23% ($9โ€“$27) 10% ($0โ€“$3) Stronger Trend CBIO
Beta / 30D Volatility Risk Regime 1.41ฮฒ ยท 62% Vol 1.47ฮฒ ยท 79% Vol Lower Realized Risk CBIO
Unified Institutional Score Composite Signal 37.4 / 100 (SELL) 48.6 / 100 (HOLD) Higher Composite OTLK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CBIO vs OTLK Buy Guide
CBIO BREAKDOWN
144d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OTLK BREAKDOWN
103d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 55th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live OTLK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CBIO nor OTLK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.